1. Age ≥ 18 years old at time of signing informed consent
2. Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment
a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment
3. Able to provide informed consent
You may not be if
1. Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
2. BMI \<25 kg/m2 at the time of screening
3. Unable to participate in a regular physical exercise program
4. Implanted pacemaker
5. Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study
Clareo Health | Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
